Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Recruiting · NCT04354064 · Observational (researchers observe without assigning treatment) · Lead sponsor: Washington University School of Medicine
View the official record on ClinicalTrials.gov →What this trial is about
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
Who can take part
Inclusion criteria
- Eligible healthy donors will be at least 18 years of age.
Exclusion criteria
- Healthy donors younger than 18 years of age
Where it is running
3 locations listed across 1 US state.
- Washington University School of Medicine - St Louis, Missouri, United States
- Washington University School of Medicine - St Louis, Missouri, United States
- Washington University School of Medicine - St Louis, Missouri, United States